National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 2) (No. PB 14 of 2012)

Link to law: https://www.comlaw.gov.au/Details/F2012L00723

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
PB 14 of 2012
National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 2)1
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.
Dated                                          23 March 2012
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1          Name of Instrument
         (1)           This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 2).
         (2)           This Instrument may also be cited as PB 14 of 2012.
2          Commencement
         (1)           This Instrument, except Schedule 2, commences on 1 April 2012.
         (2)           Schedule 2 to this Instrument commences on 1 April 2012, immediately after the application of section 99ADH of the National Health Act 1953 to the brand of pharmaceutical item ‘Nifedipine’ (listed drug) ‘Tablet 20 mg (controlled release)’ (form) ‘oral’ (manner of administration), ‘Adalat Oros 20 mg’ (listed brand).
3          Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)
            Schedules 1 and 2 amend the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).
Schedule 1     Amendments commencing 1 April 2012
 
[1]       Schedule 1, entry for Bisacodyl
                omit from the column headed “Claimed Price”:          4.53        substitute:             4.64
[2]       Schedule 1, entry for Bleomycin
(a)           omit from the column headed “Determined Price”:     43.96     substitute:             36.93
(b)           omit from the column headed “Claimed Price”:          83.52     substitute:             70.15
[3]       Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 8 mg
(a)           omit from the column headed “Determined Price”:     12.13     substitute:             6.74
(b)           omit from the column headed “Claimed Price”:          13.83     substitute:             9.30
[4]       Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 16 mg
                omit from the column headed “Claimed Price”:          21.52     substitute:             22.39
[5]       Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 32 mg
(a)           omit from the column headed “Determined Price”:     35.70     substitute:             26.32
(b)           omit from the column headed “Claimed Price”:          37.57     substitute:             28.82
[6]       Schedule 1, entry for Eprosartan
substitute:
Eprosartan
Tablet 400 mg (as mesylate)
Oral
Teveten
28
7.37
8.89

 
Tablet 600 mg (as mesylate)
Oral
Teveten
28
18.44
20.18

[7]       Schedule 1, entry for Erythromycin in the form Capsule 250 mg (containing enteric coated pellets)
(a)           omit from the column headed “Determined Price”:     2.49        substitute:             3.71
(b)           omit from the column headed “Claimed Price”:          4.56        substitute:             5.78
[8]       Schedule 1, entry for Frusemide in the form Tablet 20 mg
(a)           omit from the column headed “Determined Price”:     1.07        substitute:             0.90
(b)           omit from the column headed “Claimed Price”:          1.90        substitute:             1.60
[9]       Schedule 1, entry for Frusemide in the form Tablet 40 mg
(a)           omit from the column headed “Determined Price”:     1.96        substitute:             1.65
(b)           omit from the column headed “Claimed Price”:          4.04        substitute:             3.39
[10]     Schedule 1, entry for Glipizide
(a)           omit from the column headed “Determined Price”:     4.40        substitute:             5.09
(b)           omit from the column headed “Claimed Price”:          7.73        substitute:             8.42
[11]     Schedule 1, after entry for Norfloxacin
insert in the columns in the order indicated:
Olmesartan
Tablet containing olmesartan medoxomil 20 mg
Oral
Olmetec
30
9.50
10.37

 
Tablet containing olmesartan medoxomil 40 mg
Oral
Olmetec
30
20.17
21.04

[12]     Schedule 1, entry for Oxazepam in the form Tablet 15 mg
(a)           omit from the column headed “Determined Price”:     0.93        substitute:             1.07
(b)           omit from the column headed “Claimed Price”:          3.27        substitute:             3.41
[13]     Schedule 1, entry for Ranitidine in the form Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL
(a)           omit from the column headed “Determined Price”:     6.65        substitute:             7.87
(b)           omit from the column headed “Claimed Price”:          7.61        substitute:             8.83
[14]     Schedule 1, after entry for Tamoxifen
insert in the columns in the order indicated:
Telmisartan
Tablet 40 mg
Oral
Micardis
28
6.74
8.48

 
Tablet 80 mg
Oral
Micardis
28
19.56
21.29

[15]     Schedule 2, after entry for Eprosartan in the form Tablet 400 mg (as mesylate)
insert in the columns in the order indicated:
 
Tablet 600 mg (as mesylate)
Oral
Teveten
Adverse effects occurring with all of the base-priced drugs.
Drug interactions occurring with all of the base-priced drugs. 
Drug interactions expected to occur with all of the base-priced drugs.
Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance. 
[16]     Schedule 2, after entry for Naratriptan
insert in the columns in the order indicated:
Olmesartan
Tablet containing olmesartan medoxomil 20 mg
Oral
Olmetec
Adverse effects occurring with all of the base-priced drugs.
Drug interactions occurring with all of the base-priced drugs. 
Drug interactions expected to occur with all of the base-priced drugs.
Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance. 

 
Tablet containing olmesartan medoxomil 40 mg
Oral
Olmetec
Adverse effects occurring with all of the base-priced drugs.
Drug interactions occurring with all of the base-priced drugs. 
Drug interactions expected to occur with all of the base-priced drugs.
Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance. 

 
[17]     Schedule 2, after entry for Ranitidine in the form Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL
insert in the columns in the order indicated:
Telmisartan
Tablet 40 mg
Oral
Micardis
Adverse effects occurring with all of the base-priced drugs.
Drug interactions occurring with all of the base-priced drugs. 
Drug interactions expected to occur with all of the base-priced drugs.
Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance. 

 
Tablet 80 mg
Oral
Micardis
Adverse effects occurring with all of the base-priced drugs.
Drug interactions occurring with all of the base-priced drugs. 
Drug interactions expected to occur with all of the base-priced drugs.
Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schedule 2     Nifedipine amendments
 
 
[1]    Schedule 1, entry for Nifedipine
omit:
 
Tablet 20 mg (controlled release)
Oral
Adalat Oros
20 mg
30
9.56
11.43
 
[2]    Schedule 2, omit entry for Nifedipine
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.  See http://www.frli.gov.au.